Literature DB >> 19147907

alpha-Thalassaemia in Tunisia: some epidemiological and molecular data.

H Siala1, F Ouali, T Messaoud, A Bibi, S Fattoum.   

Abstract

Unlike the other haemoglobinopathies, few researches have been published concerning alpha-thalassaemia in Tunisia. The aim of the present work is to acquire further data concerning alpha-thalassaemia prevalence and molecular defects spectrum in Tunisia, by collecting and studying several kinds of samples carrying alpha-thalassaemia. The first survey conducted on 529 cord blood samples using cellulose acetate electrophoresis, have displayed the prevalence of 7.38% Hb Bart's carriers at birth. Molecular analyses were conducted by PCR and DNA sequencing on 20 families' cases from the above survey carrying the Hb Bart's at birth and on 10 Hb H diseased patients. The results showed six alpha-globin gene molecular defects and were responsible for alpha-thalassaemia: -alpha(3.7), - -(MedI), alpha(TSaudi), alpha(2)(cd23GAG->Stop), Hb Greone Hart: alpha(1)(119CCT->TCT) corresponding to 11 genotypes out of which two are responsible for Hb H disease (- -(Med)/-alpha(3.7)) and (alpha(TSaudi)alpha/alpha(TSaudi)alpha) and a newly described polymorphism: alpha+6C->G. The geographical repartition of alpha-thal carriers showed that the -alpha3.7 deletion is distributed all over the country, respectively the alpha(HphI) and alpha(TSaudi) seem to be more frequent in the central region of the northeast region. The haematological and clinical data showed a moderate phenotype with a late age of diagnosis for Hb H disease. This work had permitted, in addition to an overview on alpha-thalassaemia in the country, the optimization of protocols for alpha-thalassaemia detection in our lab, allowing further investigations concerning phenotype-genotype correlation in sickle cell disease or beta-thalassaemia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19147907     DOI: 10.1007/s12041-008-0036-0

Source DB:  PubMed          Journal:  J Genet        ISSN: 0022-1333            Impact factor:   1.166


  23 in total

1.  Hb Bart's levels in cord blood and alpha-thalassemia mutations in Cyprus.

Authors:  K Kyriacou; A Kyrri; E Kalogirou; P Vasiliades; M Angastiniotis; P A Ioannou; M Kleanthous
Journal:  Hemoglobin       Date:  2000-08       Impact factor: 0.849

2.  Molecular basis of beta-thalassemia in the population of Tunisia.

Authors:  Slaheddine Fattoum; Taeib Messaoud; Amina Bibi
Journal:  Hemoglobin       Date:  2004-08       Impact factor: 0.849

3.  First description in Tunisia of a point mutation at codon 119 (CCT-->TCT) in the alpha1-globin gene: Hb Groene Hart in association with the -alpha3.7 deletion.

Authors:  Hajer Siala; Faida Ouali; Taieb Messaoud; Rachida Sfar; Slaheddine Fattoum
Journal:  Hemoglobin       Date:  2005       Impact factor: 0.849

Review 4.  [Alpha-thalassemia in the north-east of Tunisia: three cases of hemoglobinopathy H].

Authors:  F Guemira; J Souilem; B Issaoui; T Messaoud; S Abbes; A Ben Abdeladhim; S Fattoum
Journal:  Tunis Med       Date:  1992-10

5.  [Detection of alpha-thalassemia in Tunisia (across 1500 cases)].

Authors:  S Fattoum; S Abbes; A Ben Abdeladhim; H Zayani; F Turki; F Guemira; M Sellami; A Ghanem; M Boussen
Journal:  Tunis Med       Date:  1987-12

6.  [Epidemiologic study of hemoglobinopathies in the Congo in 2,257 newborn infants].

Authors:  M Djembo-Taty; M Tchiloemba; F Galacteros; J Rosa; P Lissouba
Journal:  Nouv Rev Fr Hematol       Date:  1986

Review 7.  alpha-Thalassaemia.

Authors:  D R Higgs
Journal:  Baillieres Clin Haematol       Date:  1993-03

8.  Rapid detection of point mutations and polymorphisms of the alpha-globin genes by DGGE and SSCA.

Authors:  K L Harteveld; A J Heister; P C Giordano; M Losekoot; L F Bernini
Journal:  Hum Mutat       Date:  1996       Impact factor: 4.878

9.  Alpha thalassaemia in Sardinian newborns.

Authors:  R Galanello; L Maccioni; R Ruggeri; L Perseu; A Cao
Journal:  Br J Haematol       Date:  1984-10       Impact factor: 6.998

10.  alpha-Thalassaemia in the population of Cyprus.

Authors:  E Baysal; M Kleanthous; G Bozkurt; A Kyrri; E Kalogirou; M Angastiniotis; P Ioannou; T H Huisman
Journal:  Br J Haematol       Date:  1995-03       Impact factor: 6.998

View more
  6 in total

1.  The epidemiology of abnormal hemoglobins in Mediterranean high-level athletes.

Authors:  Imed Touhami; Slaheddine Fattoum; Amina Bibi; Hajer Siala; Taieb Messaoud; Donia Koubaa; Rafik Mankai; Zakia Bartagi; Daniel Le Gallais
Journal:  Eur J Appl Physiol       Date:  2009-12-16       Impact factor: 3.078

2.  Molecular spectrum of α-globin gene mutations in the Aegean region of Turkey: first observation of three α-globin gene mutations in the Turkish population.

Authors:  Hüseyin Onay; Ayça Aykut; Emin Karaca; Asude Durmaz; Aslı Ece Solmaz; Özgür Çoğulu; Yeşim Aydınok; Canan Vergin; Ferda Özkınay
Journal:  Int J Hematol       Date:  2015-05-05       Impact factor: 2.490

3.  Alpha-thalassemia mutations in adana province, southern Turkey: genotype-phenotype correlation.

Authors:  Sevcan Tug Bozdogan; Ozge Ozalp Yuregir; Nurhilal Buyukkurt; Huseyin Aslan; Zeynep Canan Ozdemir; Tomasz Gambin
Journal:  Indian J Hematol Blood Transfus       Date:  2014-06-13       Impact factor: 0.900

4.  Epidemiological profile of common haemoglobinopathies in Arab countries.

Authors:  Hanan A Hamamy; Nasir A S Al-Allawi
Journal:  J Community Genet       Date:  2012-12-08

5.  Association between clinical expression and molecular heterogeneity in β-thalassemia Tunisian patients.

Authors:  L Jouini; C A Sahli; N Laaouini; F Ouali; I Ben Youssef; B Dakhlaoui; R Othmeni; F Ouennich; S Hadj Fredj; H Siala; M Becher; N E Toumi; S Fattoum; R Hafsia; A Bibi; T Messaoud
Journal:  Mol Biol Rep       Date:  2013-09-25       Impact factor: 2.316

6.  Genotype-phenotype correlation in patients with deletional and nondeletional mutations of Hb H disease in Southwest of Iran.

Authors:  Mohammad Hamid; Bijan Keikhaei; Hamid Galehdari; Alihossein Saberi; Alireza Sedaghat; Gholamreza Shariati; Marziye Mohammadi-Anaei
Journal:  Sci Rep       Date:  2022-03-22       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.